Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of SHR-1819 Injection in adults with moderate-to-severe atopic dermatitis
CTR20232559Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Aug 2023; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20232559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232559.